(IN BRIEF) MorphoSys AG has completed its voluntary delisting from the Frankfurt Stock Exchange and Nasdaq Global Market following its acquisition by Novartis. The delisting agreement, announced on June 20, 2024, and the subsequent delisting purchase offer by Novartis were … Read the full press release
Posted in Business, Economy, Environment, Financial, Germany, Government, Industrial, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acquisition, Frankfurt, MorphoSys, NASDAQ, Novartis, Novartis BidCo AG, partnership, sustainability, Switzerland
(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release
(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in treating relapsing multiple sclerosis (RMS) over a span of up to six years. The study, presented at the American Academy … Read the full press release
(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release
(IN BRIEF) Novartis, a leading pharmaceutical company, presented its ‘pure play’ innovative medicines strategy and focused Research and Development (R&D) pipeline at an event in London. The company’s CEO, Vas Narasimhan, emphasized Novartis’ transformation into an innovative medicines-focused firm, highlighting … Read the full press release
Posted in Business, Industrial, Management, Media, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 'Pure Play' Innovative Medicines Strategy, London Event, Novartis, R&D Pipeline, Vas Narasimhan
(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release
(IN BRIEF) Sandoz Group AG, a Novartis spin-off, officially listed its shares at the SIX Swiss Exchange. With an opening share price of CHF 24.00, the market capitalization of Sandoz reached approximately CHF 10.3 billion. Sandoz’s issued share capital consists … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Switzerland
Tagged Financial, investment, Jos Dijsselhof, Novartis, partnership, Richard Saynor, Sandoz Group, shares, SIX Swiss Exchange
(IN BRIEF) Novartis has announced successful results from its Phase III NETTER-2 trial involving Lutathera, a treatment for neuroendocrine tumors (NETs). When used as a first-line treatment in combination with long-acting octreotide, Lutathera significantly improved progression-free survival in patients with … Read the full press release
(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz Group AG shares and ADRs scheduled to begin on October 4, 2023. This comes after receiving shareholder approval and key … Read the full press release
Posted in Business, Financial, Investment, Pharma & Biotech, Switzerland
Tagged ADRs, American Depositary Receipts, Novartis, Novartis ADR, OTCQX®, Sandoz, Sandoz Group AG, SDZ, shareholder, shares, SIX Exchange Regulation, SIX Swiss Exchange, SLI®, spin-off, SPI®, Swiss indices, Swiss Leader Index, Swiss Performance Index
TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase III trials for remibrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, targeting chronic spontaneous urticaria (CSU). The REMIX-1 and REMIX-2 … Read the full press release
(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release
Posted in Business, Denmark, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharma, Board of Directors, CEO, Charl van Zyl, CNS, Deborah Dunsire, Eli Lilly, H. Lundbeck A/S, immunology, Lars Rasmussen, Lundbeck, Neurology, Novartis
(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, United Kingdom
Tagged 7th annual European Patients as Partners®, biotechnology, Boehringer Ingelheim, Center for BME Health, clinical development, clinical research, Clinical Research conference, clinical trials, Community Engagement, CSL Behring, Deirdre BeVard, Diversity in Clinical Research, drug development, government, Health Equity, Healthcare, Hospital, Lundbeck, Medicine Development, Medicine Lifestyle, Medicines Development, Novartis, Patient Advocacy, Patient Centricity, Patient Communities, patient engagement, Patient Perspective, Patient Recruitment, Patient Retention, Patient Voice, Patients as Partners, Pharmaceutical, research and development, Sanofi, The Conference Forum, Thistle Hotel Marble Arch, Valerie Bowling
(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Switzerland
Tagged antibiotics, Biologics Plant, Dr Robert Golob, Glenn Gerecke, investment, Lendava, Novartis, partnership, Richard Saynor, Sandoz, Slovenia
(NOTICIA EN BREVE) Gilbert Ghostine ha sido designado presidente designado de la nueva junta directiva de Sandoz, tras el anuncio de la junta directiva de Novartis. La nueva Junta Directiva de Sandoz se formará en la segunda mitad de 2023, … Read the full press release
Posted in Business, Management, News, Pharma & Biotech, Switzerland
Tagged appointment, cita, Danone, Diageo, Firmenich, Four Seasons Hotels & Resorts, Gilbert Ghostine, leadership, liderazgo, Novartis, Sandoz
(IN BRIEF) Gilbert Ghostine has been appointed as Chairman-designate of the new Board of Directors of Sandoz, following the announcement by Novartis Board of Directors. The new Board of Directors of Sandoz will be formed in the second half of … Read the full press release
Posted in Business, Management, News, Pharma & Biotech, Switzerland
Tagged appointment, Danone, Diageo, Firmenich, Four Seasons Hotels & Resorts, Gilbert Ghostine, leadership, Novartis, Sandoz
Sandoz obtiene capacidades y activos significativos en el desarrollo de dispositivos médicos y medicamentos que apuntan a importantes oportunidades de crecimiento en genéricos complejos y respiratorios Las enfermedades respiratorias son la principal causa de muerte y discapacidad e imponen una … Read the full press release
Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide Acquisition … Read the full press release
(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. This … Read the full press release
Posted in Education, Healthcare, Internet & Online, News, Pharma & Biotech, Science, Technology
Tagged 6th annual EU Patients as Partners, AbbVie, Biotech, clinical development, clinical research, clinical trial, clinical trials, Conference, Conference Forum, data, dct, decentralized, DNA, EMD Serono, Gilead Sciences, GSK, INNOVATION, Ipsen, Janssen, Johnson & Johnson, Medicines Development, Merck KGaA, Michaela Dinboeck, MS trial, Noema Pharma, Novartis, Parkinsons disease, patient engagement, patient input, Patient Voice, patients, Patients as Partners Europe, Pfizer, pharma, Pharmaceutical, Pierre Fabre, Regeneron, Takeda, UCB
(PRESS RELEASE) AMERSFOORT, 13-Sep-2021 — /EuropaWire/ — Nutreco, a global leader in animal nutrition and aquafeed, has announced the appointment of Paul Bestford as the company’s new Chief Procurement Officer (CPO). Paul is coming from Burberry where he led the … Read the full press release
(PRESS RELEASE) BASEL, 22-Mar-2021 — /EuropaWire/ — Swiss multinational pharmaceutical Novartis appoints Karen L. Hale as Chief Legal Officer. She succeeds Shannon Klinger. Karen will be based in Basel, Switzerland and will join the Executive Committee of Novartis (ECN) and … Read the full press release
Posted in Law, News, Pharma & Biotech, Switzerland
Tagged Abbott, AbbVie, appointment, CEO, Chief Legal Officer, College of William and Mary, compliance, Duke University, healthcare legal, Karen L. Hale, legal, M.D., Novartis, Pharmaceutical, racial justice, Shannon Klinger, Sidley & Austin, Tom Kendris, Vas Narasimhan
Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients. Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years. Researchers … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Society, Switzerland, United Kingdom
Tagged Africa, African genetic diversity, Chagas disease, drug therapeutics, genetic diversity, Genomic, GSK, Human genetics, Leprosy, Lutz Hegemann M.D., malaria, Novartis, Pauline Williams, Prof. Glenda Gray, Project Africa GRADIENT, SAMR, scientific research, sickle cell disease, South African Medical Research Council, therapeutics, tuberculosis
The energy will be generated by the 179.9 MW TICO Wind Farm, located in the Spanish province of Zaragoza, Enel Green Power will be a “Green Enabler” for Novartis, supporting the company along its environmental sustainability journey (PRESS RELEASE) ROME, … Read the full press release
Posted in Energy, Gas & Oil, Environment, Industrial, Infrastructure & Utilities, Italy, News, Pharma & Biotech, Switzerland, Technology
Tagged carbon-neutrality, climate change, Enel Green Power, Enel Group, environmental sustainability, Green Enabler, greenhouse gas, Javier Vaquerizo, Montse Montaner, Novartis, renewable electricity, renewable energy, renewable power, sustainability, TICO Wind Farm, virtual power purchase agreement, VPPA, wind farm, Zaragoza
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1 Patients with early persistent fluid treated with Beovu experienced greater … Read the full press release
The initiative aims at transforming the way companies are valued (PRESS RELEASE) FRANKFURT AM MAIN, 22-Aug-2019 — /EuropaWire/ — Deutsche Bank has announced it is joining the value balancing alliance e.V.. Established as a non-profit organization the alliance was founded … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Germany, Investment, Management, News, Society
Tagged accounting, artificial-intelligence, BASF, Berthold Fürst, Bosch, capital markets, Christian Sewing, company valuation, Deloitte, Deutsche Bank, digitalisation, EY, globalisation, KPMG, LafargeHolcim, Novartis, OECD, Philip Morris International, PwC, SAP, SK, sustainability, value balancing alliance
(PRESS RELEASE) BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz’s current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis. The change is made as the current CEO of Sandoz, a … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Switzerland
Tagged ad-interim CEO, appointment, biosimilar products, CEO, Francesco Balestrieri, generics, leadership, medicine, Novartis, Richard Francis, Sandoz, Sandoz transformation, transformation, transformative treatments, Vas Narasimhan
Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has a leading development portfolio in non-viral liver diseases, including NASH There are currently no … Read the full press release
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release
Posted in European Union, Healthcare, Pharma & Biotech, Switzerland
Tagged BRAFmutation, dabrafenib, inhibitor, Mekinist®, melanoma, Novartis, Tafinlar®, trametinib, tumor
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r pediatric B-cell ALL and r/rDLBCL Novartis is the only company with an approved … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged CTL019, European Commission, Kymriah, leukemia, lymphoblastic, lymphoblastic_leukemia, Novartis, tisagenlecleucel
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase inhibitor with or without a CDK4/6 inhibitor[1] Approximately 40% of HR+ advanced breast cancer … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged breast_cancer, BYL719, Cancer, inhibitor, Novartis, oncology, PI3K
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally[1] Since the start of the donation program in … Read the full press release
Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018 Recent survey reveals 82% of people 60+ are willing to have advanced surgical options … Read the full press release
Brentford, UK, 05-Jun-2018 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*). The transaction, which was previously announced on 27 … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged buyout, Consumer HealthCare, GlaxoSmithKline plc, Healthcare, Novartis, shareholders
European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC … Read the full press release
Posted in European Union, Germany, Healthcare, Pharma & Biotech
Tagged Europe, European Commission, infliximab, Novartis, Richard Francis, Sandoz, Zessly®
Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab. Sandoz stands behind … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Biologics Licensing Application, Biosimilar, medicine, Novartis, rituximab, Sandoz, US FDA
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged CAR-T, FDA, Kymriah, leukemia, Liz Barrett, lymphoma, Novartis, oncology, Stephen J. Schuster MD, tisagenlecleucel
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics Novartis continues to embrace emerging … Read the full press release
Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%[1] Promacta is the only TPO receptor agonist indicated for the treatment of patients … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
